Relationships of depression and antidepressant use with epigenetic age acceleration and all-cause mortality among postmenopausal women.
Aging (Albany NY)
; 16(10): 8446-8471, 2024 05 27.
Article
em En
| MEDLINE
| ID: mdl-38809417
ABSTRACT
We investigated relations of depressive symptoms, antidepressant use, and epigenetic age acceleration with all-cause mortality risk among postmenopausal women. Data were analyzed from ≤1,900 participants in the Women's Health Initiative study testing four-way decomposition models. After a median 20.4y follow-up, 1,161 deaths occurred. Approximately 11% had elevated depressive symptoms (EDS+), 7% were taking antidepressant medication at baseline (ANTIDEP+), while 16.5% fell into either category (EDS_ANTIDEP+). Baseline ANTIDEP+, longitudinal transition into ANTIDEP+ and accelerated epigenetic aging directly predicted increased mortality risk. GrimAge DNA methylation age acceleration (AgeAccelGrim) partially mediated total effects of baseline ANTIDEP+ and EDS_ANTIDEP+ on all-cause mortality risk in socio-demographic factors-adjusted models (Pure Indirect Effect >0, P < 0.05; Total Effect >0, P < 0.05). Thus, higher AgeAccelGrim partially explained the relationship between antidepressant use and increased all-cause mortality risk, though only prior to controlling for lifestyle and health-related factors. Antidepressant use and epigenetic age acceleration independently predicted increased all-cause mortality risk. Further studies are needed in varying populations.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pós-Menopausa
/
Metilação de DNA
/
Epigênese Genética
/
Depressão
/
Antidepressivos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article